Albiglutide: Is a better hope against diabetes mellitus?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2015.12.015PMID 26796275
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reactive oxygen species: friend or foe?

  2015cited by this paper
• Correction: Prediabetes: grounds of pitfall signalling alteration for cardiovascular disease

  2015cited by this paper
• Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats.

  2014cited by this paper
• Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP‐1R activation

  2014cited by this paper
• Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.

  2014cited by this paper
• The current state of diabetes mellitus in India.

  2014cited by this paper
• Circadian Secretion of the Intestinal Hormone GLP-1 by the Rodent L Cell

  2014cited by this paper
• Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide

  2014cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.

  2014cited by this paper
• HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

  2014cited by this paper
• Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

  2014cited by this paper
• A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

  2014cited by this paper
• Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

  2014cited by this paper
• Once-weekly albiglutide in the management of type 2 diabetes: patient considerations

  2014cited by this paper
• Diabetes mellitus associated cardiovascular signalling alteration: a need for the revisit.

  2013cited by this paper
• Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.

  2013cited by this paper
• Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.

  2013cited by this paper
• IDF Diabetes Atlas : sixth edition

  2013cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on renal function.

  2013cited by this paper
• Signalling mechanisms involved in renal pathological changes during cisplatin-induced nephropathy

  2013cited by this paper
• Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?

  2013cited by this paper
• Retinal Pigment Epithelial Cells Express a Functional Receptor for Glucagon-Like Peptide-1 (GLP-1)

  2013cited by this paper
• Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis

  2012cited by this paper
• Liraglutide‐Induced Acute Kidney Injury

  2012cited by this paper
• Regulation of calcium in pancreatic α- and β-cells in health and disease

  2012cited by this paper
• Effects of Multiple Doses of Albiglutide on the Pharmacokinetics, Pharmacodynamics, and Safety of Digoxin, Warfarin, or a Low-Dose Oral Contraceptive

  2012cited by this paper
• Colony‐Stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non–Small Cell Lung Cancer Who Were Receiving Chemotherapy

  2012cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012cited by this paper
• Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

  2011cited by this paper
• IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

  2011cited by this paper
• The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review

  2011cited by this paper
• IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.

  2011cited by this paper
• Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency

  2011cited by this paper
• Gold Sodium Thiomalate for the Treatment of Rheumatoid Arthritis in a Patient with Hepatitis B

  2011cited by this paper
• Emerging treatment options for type 2 diabetes.

  2010cited by this paper
• Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

  2010cited by this paper
• Tackling obesity: new therapeutic agents for assisted weight loss

  2010cited by this paper
• Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A

  2010cited by this paper
• Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes.

  2009cited by this paper
• Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

  2009cited by this paper
• Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?

  2009cited by this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

  2009cited by this paper
• Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects

  2009cited by this paper
• Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

  2008cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts

  2006cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

  2004cited by this paper
• Circulation and Degradation of GIP and GLP-1

  2004cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003cited by this paper
• Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor.

  2003cited by this paper
• Glucagon-Like Peptide 1 Induces Pancreatic β-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor

  2003cited by this paper
• SUR1 Regulates PKA-independent cAMP-induced Granule Priming in Mouse Pancreatic B-cells

  2003cited by this paper
• Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

  2002cited by this paper
• Nitric oxide inhibits calcium release from sarcoplasmic reticulum of porcine tracheal smooth muscle cells.

  1997cited by this paper
• Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I

  1996cited by this paper
• Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

  1985cited by this paper
• A gastric inhibitory polypeptide. II. The complete amino acid sequence.

  1971cited by this paper
• Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects.

  1967cited by this paper
• NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.

  1964cited by this paper
• PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.

  1964cited by this paper
• DEFECT OF ORGANIZATION IN THE EXTERNAL EAR.

  1824cited by this paper

• A Systematic Review On Bovine Serum Albumin Nanoparticle: Preparation And Therapeutic Application

  2025cites this paper
• Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases

  2025cites this paper
• Genetic-epigenetic targets for PCOS-associated diabesity.

  2025cites this paper
• Advances in Oral Biomacromolecule Therapies for Metabolic Diseases

  2025cites this paper
• Transcriptome analysis reveals the regulatory effects of Bacillus amyloliquefaciens and Bacillus pumilus on immune and digestive related genes in the spleen of weanling black goats

  2023cites this paper
• Synthesis, molecular docking, and pharmacological evaluation of 5-(4-(2-(5-ethyl pyridine-2-yl) ethoxy) benzyl)-3-(phenylsulfonyl) thiazolidine-2, 4-dione against HFD-induced diabesity via interaction with the CB1 receptor

  2022influential citation
• The Role of Aerobic Exercise in the Gene Expression of Metallo Proteinase-2 and Angiostatin in Diabetic Rats' Heart Tissue

  2022cites this paper
• Preliminary investigation on impact of intergenerational treatment of resveratrol endorses the development of 'super-pups'.

  2022cites this paper
• Targeting the endocannabinoid system in diabesity: fact or fiction?

  2021cites this paper
• Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis

  2021cites this paper
• EFFECTS OF DIABETES

  2019cites this paper
• Temporal dynamics of pre and post myocardial infarcted tissue with concomitant preconditioning of aerobic exercise in chronic diabetic rats

  2019cites this paper
• Preparation and in Vitro Analysis of Human Serum Albumin Nanoparticles Loaded with Anthracycline Derivatives.

  2018cites this paper
• Nano-medicine and Vascular Endothelial Dysfunction: Options and Delivery Strategies

  2018cites this paper
• Combined and individual strategy of exercise generated preconditioning and low dose copper nanoparticles serve as superlative approach to ameliorate ISO-induced myocardial infarction in rats

  2018cites this paper
• Glucagon-like peptide-1 improves β-cell dysfunction by suppressing the miR-27a-induced downregulation of ATP-binding cassette transporter A1.

  2017cites this paper
• Peptides and Diabetes 2 PEPTIDES FOR DIABETES RESEARCH

  2017cites this paper
• Albiglutide-induced pancreatitis

  2016cites this paper
• Albumin in Medicine

  2016cites this paper
• Synthesis and preliminary therapeutic evaluation of copper nanoparticles against diabetes mellitus and -induced micro- (renal) and macro-vascular (vascular endothelial and cardiovascular) abnormalities in rats

  2016cites this paper
• Stability of Albumin and Stabilization of Albumin Preparations

  2016cites this paper